Abstract Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist with psychotogenic and dissociative e¤ects in healthy humans. These cognitive and perceptual e¤ects in humans are reportedly reduced by benzodiazepine premedication. This study assessed the interactive e¤ects of a ketamine (IV bolus of 0.26 mg / kg followed by an infusion of 0.65 mg / kg per hour) and lorazepam 2 mg., PO, in humans. Twentythree healthy subjects completed 4 test days involving the oral administration of lorazepam or matched placebo 2 h prior to the IV infusion of ketamine or placebo. Ketamine : 1) produced behaviors similar to the positive and negative symptoms of schizophrenia as assessed by the Brief Psychiatric Rating Scale (BPRS); 2) evoked perceptual alterations as measured by the Clinician-Administered Dissociative States Scale (CADSS); 3) impaired performance on the Wisconsin Card Sorting Test (WCST) and other tests sensitive to frontal cortical impairment; and 4) had amnestic e¤ects. Lorazepam produced attention impairments, concrete proverb interpretations, and recall impairments. Lorazepam reduced ketamine-associated emotional distress and there was a non-signiÞcant trend for it to decrease perceptual alterations produced by ketamine. However, it failed to reduce many cognitive and behavioral e¤ects of ketamine, including psychosis. Further, lorazepam exacerbated the sedative, attentionimpairing, and amnestic e¤ects of ketamine. There was no evidence of pharmacokinetic interaction between these medications. These data suggest that subhypnotic lorazepam and ketamine show a spectrum of interactive e¤ects, ranging from antagonism to potentiation.
Introduction
There is growing interest in the human psychopharmacology of N-methyl-D-aspartate (NMDA) receptor function in light of evidence implicating glutamate in higher cortical functions and psychiatric illness (Kim et al. 1980; Deutsch et al. 1989; Carlsson and Carlsson 1990; Javitt and Zukin 1991; Olney and Farber 1995) . The NMDA receptor subclass is the site of action of PCP and ketamine (Anis et al. 1983) . These drugs bind non-selectively to NMDA receptor subtypes (Anis et al. 1983; Yamakura et al. 1993; Bresink et al. 1995) . At subanesthetic doses, PCP is a selective noncompetitive NMDA antagonist (Javitt and Zukin 1991) . Ketamine is 1050 times less potent than PCP in binding to the NMDA receptor (Hampton et al. 1982) , blocking NMDA-mediated neurotoxicity (Rothman and Olney 1987) , seizures (Willetts et al. 1990 ), physiological e¤ects (Byrd 1987) , and in substituting for phencyclidine in drug discrimination paradigms (cf. Javitt and Zukin 1991) . Ketamine is clinically available as a racemic mixture of two enantiomers. The S-isomer has 2 4 times greater a¦nity and selectivity for the NMDA receptor and greater clinical potency than the R-isomer (Øye et al. 1991 , 1992 Zeilhofer et al. 1992) .
NMDA antagonists have been of great interest to psychiatry because their behavioral e¤ects resembled aspects of schizophrenia and dissociative states (Luby et al. 1959; Domino et al. 1965; Øye et al. 1992; Krystal et al., 1994; Malhotra et al. 1996) . These drugs also received attention as drugs of abuse (Siegel 1978; Smith et al. 1978) . Recently, the subanesthetic dose-related e¤ects of ketamine in healthy humans were characterized using measures employed in the assessment of schizophrenia and dissociative states (Krystal et al. 1994; Malhotra et al. 1996) . Ketamine produced 1) positive symptoms of psychosis, such as illusions, disturbances in thought organization, and delusions; 2) negative symptoms similar to those associated with schizophrenia, including blunted emotional responses, emotional detachment, and psychomotor retardation; 3) perceptual alterations reminiscent of dissociative states, such as slowing of time perception, altered body perception, depersonalization, derealization, and distorted sensory perception; 4) impairments on tests of frontal cortical function including increased distractibility, reduced verbal ßuency, and poorer performance on the Wisconsin Card Sorting Test; and 5) learning impairments dependent on the dose of ketamine and the duration between stimulus presentation and testing. These ketamine responses are similar to the emergence phenomena associated with waking from ketamine anesthesia including perceptual alterations, vivid dreams, and delirium (Knox et al. 1970; Collier 1972; White et al. 1982 ) that limit its clinical anesthetic utility.
Benzodiazepine premedication is an established strategy for reducing dysphoric symptoms associated with emergence from ketamine anesthesia (Coppel et al. 1973; Dundee et al. 1979; Zsigmond and Domino 1980; White et al. 1982) . The benzodiazepines diazepam (Kothary and Zsigmond 1977; Tucker et al. 1984) , ßunitrazepam (Freuchen et al. 1976) , lorazepam Lilburn et al. 1978) , and midazolam (White 1982; Cartwright and Pingel 1984; Toft and Romer 1987; Restall et al. 1988 ) have been reported to reduce the emergence phenomena. Further, administration of the benzodiazepine receptor antagonist, ßumazenil, increases emergence phenomena in patients treated with midazolam and ketamine (Restall et al. 1990 ). Benzodiazepines have also been reported to reduce the psychotogenic e¤ects of PCP intoxication (Smith et al. 1978) .
Although benzodiazepines clearly increase ketamine tolerability, methodological shortcomings of the published literature limit precise conclusions regarding the interactive cognitive and behavioral e¤ects of these drugs . Few published studies employed double-blind designs or randomized assignment to groups (Kothary and Zsigmond 1977; Freuchen et al. 1976; White 1982) . Also, only one study used a validated rating scale for assessing hallucinatory behavior (Migály et al. 1991 ). In addition, many reports employed retrospective symptom assessments (Cartwright and Pingel 1984; Tucker et al. 1984; Toft and Romer 1987; Restall et al. 1988) . Retrospective reports are suspect for studies evaluating the interactive e¤ects of ketamine and benzodiazepines because both agents have potent amnestic e¤ects (White 1982; Ghoneim et al. 1984 Ghoneim et al. , 1985 Roache and Gri¦ths 1987; Øye et al. 1992; Krystal et al. 1994 ). In addition, the published studies did not insure that emergence symptoms were assessed at identical ketamine blood levels in patients receiving ketamine or ketamine plus benzodiazepines. Benzodiazepine co-administration may increase the duration of somnolence following ketamine administration . As a result, emergence symptoms may have appeared to be reduced in benzodiazepine-treated patients because awakening occurred at lower ketamine blood levels. The methodologic limitations of the published reports are of particular concern because several studies suggest that subhypnotic benzodiazepine doses do not prevent ketamine emergence phenomena (Bovill et al. 1971; Loh et al. 1972; Pandit et al. 1980) .
The current study assessed the interactive e¤ects of subanesthetic ketamine and subhypnotic lorazepam in humans in a double-blind placebo-controlled design. It evaluated the capacity of lorazepam to reduce the psychotogenic, dissociative, cognitive, physiologic, and neuroendocrine e¤ects of ketamine in humans. This study administered ketamine as an initial bolus followed by a slow infusion in order to sustain ketamine e¤ects during the assessment period. A subhypnotic and routinely prescribed clinical dose of oral lorazepam, 2 mg, was selected in order to avoid excessive sedation that would interfere with cognitive assessments.
Materials and methods

Subjects
Subjects were recruited for participation in this study through public advertisement and paid for their participation. Healthy subjects were selected for participation after obtaining written informed consent and following a two-step process to exclude individuals with a history of psychiatric illness, substance abuse disorders, or signiÞcant current life stress. The Þrst step involved the administration of a structured diagnostic interview for non-patient populations (Spitzer et al. 1990) supplemented by a clinical interview that further evaluated personal and family history. Based on this assessment, subjects were excluded who gave evidence of a psychiatric or substance abuse disorder, history of clinical consultation for an emotional di¦culty, psychiatric illness in a Þrst degree relative, or clinically signiÞcant current life stress deÞned operationally as 3 or greater on the Severity of Psychosocial Stressors Scale for Adults employed in axis IV of DSM-III-R (American Psychiatric Association 1987). The second step was a telephone interview conducted with an individual identiÞed by the subject to conÞrm information collected from the subject. Subjects were instructed to abstain from consuming psychoactive substances for 4 weeks prior to testing. Urine toxicology screens at initial screening and on test days provided additional conÞrmatory evidence. None of the subjects reported a history of serious medical illness. All of the subjects had normal results on physical examination and laboratory testing, including liver and thyroid function tests. Subjects were all within normal limits on two measures of vulnerability to psychosis, the Bell Reality Testing Inventory [Hallucinations & Delusions : [0.4 ± 0.0 (SEM); Reality Distortion : [0.6 ± 0.0; Uncertainty of Perception : [0.9 ± 0.1; Bell et al. 1985] and the Wisconsin Scales of Psychosis Proneness (23.5 ± 2.1; Chapman et al. 1982) .
Nineteen male (age : 29.3 ± 1.8 year; weight : 84.6 ± 4.2 kg) and 11 female subjects (age : 31.3 ± 2.9 year; weight : 70.5 ± 12.2 kg) entered the study. General intellectual capacities were comparable in the men and women participating in the study as assessed by the Slosson Intelligence Test (men : 135.0 ± 3.9; women : 133.1 ± 4.4; Slosson, 1963) . Except when reported, signiÞcant gender di¤erences did not emerge in the data analysis. Thus, unless indicated, data were collapsed across genders. Educational status of subjects was as follows : two subjects were completing post-doctoral training, 13 subjects were in graduate or professional school, 11 subjects had completed college, and two subjects had completed high school. Twenty-three subjects were Caucasian, four subjects were African-American, two subjects were of Hispanic descent, and one subject was of Asian descent. Seven subjects entering the study did not proceed to completion : two subjects were terminated due to poor venous access, one subject was excluded after revealing an exclusionary medical condition following his third test day, two subjects left the study because they found ketamine e¤ects unpleasant, and two subjects withdrew due to scheduling di¦culties. On their Þrst day, 11 subjects received placebo lorazepam and placebo ketamine (placebo day), eight subjects received placebo lorazepam / active ketamine (ketamine day), six subjects received active lorazepam / active ketamine (ketamine-lorazepam day), and Þve subjects received active lorazepam / placebo ketamine (lorazepam day).
Ketamine test procedures
Ketamine administration
Subjects completed 4 test days in a randomized and balanced order under double-blind conditions during which they received lorazepam (2 mg, PO, Wyeth-Ayerst, Philadelphia, PA USA) or matched placebo 2 h before they were administered saline (0.9 % NaCl, USP) or ketamine hydrochloride (Parke-Davis, Kalamazoo, Mich., USA) as a 1-min IV bolus of 0.26 mg /kg followed by a 1-h IV infusion of 0.65 mg /kg. Test days were spaced by 37 days. The ketamine dose and administration schedule selected in this study was based on our e¤orts to produce a constant ketamine blood level throughout the study period that was similar to the estimated peak blood level of our previous study (Krystal et al. 1994) .
Behavioral ratings
Symptoms and behaviors characteristic of schizophrenia were assessed using the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 1962) . The BPRS previously was sensitive to ketamine e¤ects in humans (Krystal et al. 1994) . Four key BPRS items were selected as an index of the positive symptoms of schizophrenia based on previous reports indicating their utility and validity (Bowers et al. 1980; Kane et al. 1988; Krystal et al. 1993 ) and inclusion within the empirically-derived thought disorder factor of the BPRS (Hedlund and Vieweg 1980) . These four key positive symptoms were conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content. In evaluating hallucinatory behavior, bizarre perceptual experiences associated with an identiÞable sensory reference were rated as illusory perceptual alterations rather than hallucinations. This deÞnition was more conservative than that employed in a previous report (Krystal et al. 1994 ) and selected to provide greater clarity in data interpretation. Three key BPRS items, blunted a¤ect, emotional withdrawal, and motor retardation were selected as a measure of the negative symptoms of schizophrenia based on a report of their reliability and validity (Thiemann et al. 1987) and their inclusion within the empirically derived withdrawalretardation factor of the BPRS (Hedlund and Vieweg, 1980) . Activation and anxious depression were also assessed using factors derived from the BPRS (Hedlund and Vieweg 1980) . The items associated with the activation factor were tension, mannerisms and posturing, and excitement. The items contributing to the anxious depression factor were anxiety, guilt feelings, depressive mood, somatic concern, tension, and motor retardation.
Anxiety, drowsiness, high, irritability, and sadness were assessed using visual analog scales completed by clinician raters. These scales were scored in millimeters from the left hand side of a 100 mm line to a perpendicular mark made by the clinician at a point corresponding to the apparent magnitude of the feeling state reported and exhibited by the subject (range : 0, not at all, to 100, most ever; Charney et al. 1987) . The BPRS and analog scales were administered prior to lorazepam ([120 min) and ketamine ([15 min) administration, and 5, 60, 90, 120 and 180 min following the initiation of ketamine infusion. Ratings assessed the period following the previous assessment. Thus, the 90-min timepoint reßected the previous 30 min.
The Clinician-Administered Dissociative States Scale (CADSS; Bremner et al., in review) was a clinician-administered measure of perceptual, behavioral, and attention alterations occurring during dissociative experiences which had been validated in healthy subjects, schizophrenic patients and patients with post-traumatic stress disorder. This scale involved 19 self-report questions and eight observer ratings scored from 0 (not at all) to 4 (extremely). In order better to characterize dissociative responses to ketamine, CADSS items were sorted into Þve subscales with apparent face validity (Krystal et al. 1994 ) and based on published scales assessing dissociative states (Sanders 1986; Steinberg et al. 1990 ) : body perception, environmental perception, feelings of unreality, memory impairment, and time perception (items in each subscale available upon request). The CADSS was administered at the [150-, 5-, 60-, 90-, 120-, and 180-min timepoints. For the memory assessment, separate sets of three words, selected on the basis of their comparable frequency of use in the English language and comparable di¦culty (Kucera and Francis 1967) , were presented at each timepoint. Thus, each set of words was presented once, but recall was assessed three times : immediately following presentation, following a distracting task, and following a 10-min delay. Word lists were presented 150 min prior to ketamine infusion and at the 5-, 90-, 120-, and 180-min timepoints.
A spectrum of functions associated with the frontal cortex were assessed in this study including vigilance to visual stimuli, distractibility, verbal ßuency, abstraction, and the Wisconsin Card Sorting Test (Goldstein 1949; Milner 1964; Benton 1968; Salmaso and Denes 1982; Wilkins et al. 1987 ). Vigilance to visual stimuli was measured using a continuous performance task (Gordon 1983) in which subjects attended to numbers presented sequentially on a screen. The subject pushed a button to signal when a 9 was preceded by a 1. The distractibility task was identical to the vigilance task with the exception that numbers were presented sequentially in three contiguous columns. Subjects had to attend to the middle column and ignore the numbers presented in the outer two columns. The verbal ßuency task requires subjects to generate as many words as possible beginning with a speciÞed letter during a 1-min interval. Equivalent versions of this task were administered on the 4 test days using letters equated for frequency in English (Borkowski et al. 1967) .
Abstraction and thought disorder were evaluated by assessing the interpretation of proverbs (Gorham 1956 ). The scoring system described by Gorham has been modiÞed to increase inter-rater reliability and to assess concrete and bizarre responses. The concreteness and bizarreness of each response was rated on a three-point scale where a value of zero indicated abstract and typical responses and a value of two reßected concrete and highly unusual responses. In addition, failure to respond was coded to reßect whether the subject did not respond secondary to time limitations, physical illness, or refusal. The abstract and bizarre totals were weighted to reßect the total number of responses they represent.
The Wisconsin Card Sorting Test (WCST) is a task in which cards are sorted by the number, color, and shape of objects depicted on the card. This task requires the subject to determine the rule governing the matching of cards and to adapt when these rules shift during the task. Patients with frontal lobe lesions (Milner 1964) exhibit increased perseverative error and fewer categories successfully completed on this task. Computerized versions of the WCST activated the frontal cortex in healthy subjects in a previous study (Weinberger et al. 1986 ). The current study utilized a computerized version of the WCST developed and validated by Dr. Donald Quinlan (unpublished data) and employed in a previous ketamine study (Krystal et al. 1994) . The frontal cortical tasks were presented in a Þxed order in order to increase comparability between test days. The verbal ßuency, vigilance and distractibility tests, and the proverb tests were initiated 10 min following the ketamine bolus. The WCST was administered 40 min following the ketamine bolus.
In order to assess psychomotor function, the rate of Þnger-tapping was assessed using a telegraph key apparatus (LaFayette Instrument Co., Lafayette, Ind., USA; Halstead 1947). Subjects were instructed to tap as rapidly as possible for 10 s using their index Þnger. Subjects completed Þve successful trials, deÞned as within 10 % of the mean of the remaining trials, with each hand alternating between dominant and non-dominant hands. Brief rest period were inserted between every three tapping trials. The meaned score of the Þve successful trials are reported. Subjects completed up to ten trials in order to produce Þve successful trials. If consistency could not be established, the Þve highest scores were reported. Handedness was determined using the cerebral dominance item of the Neurological Evaluation Scale (Buchanan and Heinrichs 1989) . Twenty-Þve subjects were right-handed, four subjects were lefthanded, and one subject showed mixed dominance on the basis of this evaluation. Of the 23 subjects who completed 4 test days, one was excluded from the Þnger tapping test due to mixed dominance.
Biochemical methods
Plasma levels of prolactin, cortisol, homovanillic acid (HVA), and lorazepam were determined. Radioimmunoassay kits were utilized for determining plasma levels of prolactin [Serono Diagnostics, Inc Norwell, Mass., USA; intra-assay and interassay coe¦cients of variance (CVs) were 3 %, and 7 %, respectively], cortisol (Baxter Travenol Diagnostics, Inc., Incstar Corp, Stillwater Minn., USA; intra-assay and interassay variance were 3 % and 5 %, respectively). Plasma samples for hormonal analysis were run in duplicate pairs. Plasma free levels of HVA (Bacopoulos et al. 1979) were measured by gas chromatography and mass spectrometry using deuterated internal standards.
Plasma lorazepam was determined by high performance liquid chromatography (HPLC) by one of the authors (RS.). A 1-ml aliquot of plasma containing 40 ng of internal standard oxazepam was made alkaline with 1 ml of 0.6 M carbonate bu¤er (pH = 9.8). Methyl-tert-butyl ether : n-heptane 60 : 40 (v/v), 5 ml was added and the contents mixed for 10 min. Following centrifugation at 1500 g for 10 min, the organic layer was transferred to a tapered centrifuge tube and dried under vacuum with moderate heat (45°C). The residue was reconstituted with 250 µl of mobile phase, vortexed and transferred to small glass inserts suitable for an autosampler. Chromatographic separation was achieved using trimethylsilyl (LC-1, Supelco) reversed phase column and a mobile phase consisting of 70 % 0.05 M KH 2 PO 4 and 30 % acetonitrile with 1.2 ml triethylamine and 5.0 ml 20 % heptane sulfonate added per liter. The pH was adjusted to 3.0 with 1 ml of 85 % phosphoric acid. The ßow rate was 2.0 ml / min, which resulted in retention times of 4.7 and 5.4 minutes for oxazepam and lorazepam, respectively. An ultraviolet absorbance detector set at 230 nm permitted a linear response in the lorazepam concentration range of 3150 ng / ml. The accuracy and precision of the method was assessed by processing 12 tubes of four di¤erent concentrations (150, 50, 12.5, and 3.0 ng / ml) of lorazepam. The resulting values indicate acceptable accuracy and precision : 151 ng / ml, CV = 0.6 %; 51 ng / ml, CV = 0.8 %; 12.7 ng / ml, CV = 7.4 %; 3.1 ng / ml, CV = 14.2 %. The recovery of lorazepam from plasma did not vary within the concentration range (150 ng / ml : 79.0 ± 2.6 %; 50 ng / nl : 79.0 ± 1.3 %; 12.5 ng / nl : 78.0 ± 2.3 %; n = 10 for each concentration). Inter-assay variability based on three levels of quality controls (100, 25, 5 ng / nl) resulted in values of 105 ng / ml, CV = 3.7 %; 27 ng / ml, CV = 8.0 %, and 4.9 ng / ml, CV = 4.9 % (n = 10 days).
Plasma ketamine levels were determined by gas chromatographymass spectrometry (GC / MS) by one of the authors (PS.) in seven of the subjects. In preparing the samples, 1.0 ml of plasma was added to 0.5 ml borate bu¤er (0.1 M, pH = 9.5) and 50 µl (500 ng) internal standard (o-Br-ketamine). The samples were vortexed and 5.0 ml benzene was added. Samples were then vigorously shaken for 10 min and centrifuged at 850 g for 10 min at room temperature. A 4-ml benzene phase aliquot was transferred to disposable glass tubes and evaporated to dryness at 40°C. The residue was dissolved in 0.2 ml methanol and transferred to conical-bottomed screw-cap reaction vials and evaporated to dryness. Pentaßuoro-propionic acid anhydride (PFPAA) 40 µl was then added to each vial, vortexed, tightly capped and incubated at 65°C for 30 min. After cooling to room temperature, the derivatized sample from each vial was transferred to autosampler vials for injection and GC / MS analysis. For the chromatographic analysis, the derivatized ketamine samples were analyzed on a Hewlett-Packard Model 5987A GC / MS equipped with electron impact (EI) ionization, selected ion monitoring (SIM) and autosampler. An HP Ultra Performance fused-silica capillary column (20 mm × 0.31 mm i.d.) coated with crosslinked methyl silicone to Þlm thickness of 0.17 µM used for chromatographic separation of the sample components. The carrier gas was helium at a ßow rate of 1.0 ml / min. Instrument temperature zones were : injection port (250°C), interface oven (275°C), GC interface probe (275°C), and ion source (200°C). The column oven was set at an initial temperature of 200°C for 0.1 min, then increased at 4°C/ min to 230°C, where it was held for 0.5 min. Total run time was 8.1 min. The MS settings were : multiplier voltage (2300 V), emission current (300 µA), electron energy (70 eV) and ion detection in SIM mode. The mass ion speciÞc for both ketamine and the IS (bromo-ketamine, 160 M / Z) was monitored in SIM mode from 2.5 to 8.1 min. For data acquisition, the total ion chromatogram was plotted and the ion abundance peak heights were measured. The ketamine / internal standard peak height ratios were then used to quantitate plasma ketamine levels. Calibration curves were constructed by plotting the ion abundance peak height ratios as a function of the ketamine concentration. These data were then Þt to the ln-quadratic equation : ln(Y) = b 0 +b 1 ln(X)+b 2 [ln(X)] 2 with a least squares regression analysis. The ketamine concentrations of unknown samples were calculated using the results of the regression analyses. Under the described chromatographic conditions, the retention times for ketamine and o-Brketamine were 5.2 and 6.2 min, respectively. Calibration curve samples were prepared in triplicate by spiking 1.0 ml blank plasma with the appropriate volume of ketamine standard solution to achieve 20.0, 50.0, 100.0, and 500.0 ng ketamine / ml plasma. The accuracy and precision of the method were assessed by seeding quality control samples at drug concentrations of 50 and 200 ng ketamine / ml. Triplicate quality control samples were assayed on each of 3 consecutive days. The precision of the assay was found to have coe¦cients of variation ranging between 3.7 % and 4.9 %. The concentration means for the seeded control samples were found to be within 1.3 % and 3.1 % of the theoretical values.
Data analysis
Data were initially subjected to a repeated measures analysis of variance (RMANOVA) with within-subjects factors of ketamine (ketamine versus placebo), lorazepam (lorazepam versus placebo), and time. In the presentation, when drug (ketamine or lorazepam), time, and the drug by time interactions were all signiÞcant, only the drug by time interactions were reported. The interactive e¤ects of gender was studied as a between-subjects factor added to the RMANOVAs. Similarly, the interactive impact of emesis on neuroendocrine data was studied by adding the presence or absence of this behavior as a between-subjects factor in the repeated measures ANOVAs. When either drug by time interaction was signiÞcant, post-hoc multiple comparisons of post-infusion timepoints to baseline were conducted using the Dunnetts multiple t-test (Winer 1971) . Post-hoc within-subjects contrasts were employed to compare test days for data from cognitive tasks administered once per test day. Comparison of baseline values were conducted using paired t-tests with Bonferroni corrections to adjust for multiple comparisons. Ketamine e¤ects on the WCST show signiÞcant order e¤ects (Krystal et al., in preparation) . As a result, Wisconsin Card Sorting Test data in this report are solely from the Þrst test day for each subject. These data were compared using an ANOVA in a between subjects design. Post-hoc testing of Wisconsin Card Sorting Test results were conducted using the Fisher Protected Least SigniÞcant Di¤erence (PLSD) multiple comparison test. The relationship between baseline demographic and descriptive data and peak change post-infusion at the highest dose of ketamine was explored using Pearson correlations.
Results
Brief Psychiatric Rating Scale (BPRS)
Positive symptoms
As indicated in Fig. 1 , ketamine produced an increase in the four key positive symptoms of schizophrenia in healthy subjects (n = 23). However, lorazepam did not signiÞcantly modulate the severity of these ketamineinduced symptoms. In the RMANOVA, the interactive e¤ects of ketamine and time (F 6,132 = 73.2, P = 0.0001) were signiÞcant. Lorazepam did not signiÞcantly alter BPRS positive symptoms. There were no signiÞcant di¤erences in baseline scores between test days. Ketamine increased three of the four positive symptoms, but none of the drug interaction e¤ects attained signiÞcance. In the RMANOVA, ketamine (ketamine by time interaction : F 6,132 = 84.6, P = 0.0001), but not lorazepam, increased scores on the conceptual disorganization item. Conceptual disorganization was manifest in a variety of ways including altered rate of thoughts, increased tangentiality, and loosening of associations. For example, one subject reported I can empathize with Kramer on Seinfeld, its like Im ßoating across the Tundra, I feel like Im going to say everything that goes through my mind. I feel like Im going back and forth like Im in an earthquake. Im tangential. I can see 180 degrees. Do they pay you guys not to laugh? I dont feel my body, sounds are compacted (ketamine day, subject 21). Due to the strict deÞnition of hallucination employed in this study, all perceptual alterations were rated as illusions rather than hallucinations. As a result, there were no signiÞcant drug e¤ects on the hallucinatory behavior item of the BPRS. In the RMANOVA performed on the suspiciousness item, ketamine (ketamine by time interaction : F 6,132 = 7.8, P = 0.004), but not lorazepam signiÞcantly increased scores. The most common paranoid ideation expressed by subjects receiving ketamine was that research sta¤ and others were plotting against them. One subject complained that sta¤ inserted thoughts into his mind (ketamine day, subject no. 6). In the RMANOVA performed on the unusual thought content item, ketamine (ketamine by time interaction: F 6,132 = 59.0, P = 0.0001), but not lorazepam signiÞ-cantly increased scores. Illustrating unusual thought content, one subject noted I feel like a human apple... I feel like a giant pumpkin thats turned human ... I feel like a human computer, like a female on Star Trek (ketamine day, subject no. 16).
Negative symptoms
Ketamine, and to a lesser extent lorazepam, increased scores on BPRS items associated with the negative symptoms of schizophrenia (n = 23, Fig. 1 ). RMANOVA revealed signiÞcant e¤ects of ketamine (ketamine by time interaction : F 6,132 = 35.2, P = 0.0001) and lorazepam (lorazepam by time interaction : F 6,132 = 7.8, P = 0.0001). No other interactive e¤ects attained signiÞcance in the ANOVA. There were no signiÞcant di¤erences in baseline scores between test days.
In the RMANOVA performed on blunted a¤ect data, the ketamine by time interaction e¤ects (F 6,132 = 13.2, P = 0.0001), lorazepam by time interaction e¤ects (F 6,132 = 8.3, P = 0.0001), but not the ketamine by lorazepam by time interaction reached signiÞcance. In contrast, a post-hoc RMANOVA revealed that the ketamine-lorazepam produced greater a¤ective blunting than did ketamine (drug by time interaction :
F 6,132 = 3.2, P = 0.02). In the RMANOVA performed on the motor retardation item, the ketamine by time interaction e¤ects (F 6,132 = 17.1, P = 0.0001), lorazepam by time interaction e¤ects (F 6,132 = 5.9, P = 0.0006), and ketamine by lorazepam by time interaction (F 6,132 = 2.7, P = 0.03) reached signiÞcance. Motor retardation produced by lorazepam reßected its sedative-hypnotic e¤ects. However, subjects clearly distinguished ketamine e¤ects from sedation. For example, one subject noted I feel so distant from everything. I dont feel drowsy. I feel like it [ketamine] is keeping me awake (ketamine day, subject no. 10). Ketamine also increased emotional withdrawal. The RMANOVA performed on the emotional withdrawal data revealed a signiÞcant ketamine by time interaction (F 6,132 = 48.0, P = 0.0001), but not signiÞcant lorazepam e¤ects.
BPRS activation factor score
The RMANOVA performed on BPRS activation factor scores ( Fig. 1 ) revealed signiÞcant ketamine e¤ects (ketamine by time interaction : F 6,132 = 25.6, P = 0.0001). Neither lorazepam e¤ects nor the lorazepam-ketamine interaction e¤ects were signiÞcant.
BPRS anxious depression factor score
Lorazepam signiÞcantly reduced emotional distress associated with ketamine administration (Fig. 1) . In the RMANOVA, the e¤ects of ketamine (ketamine by time interaction : F 6,132 = 18.5, P = 0.0001); and the ketamine by lorazepam by time interaction (F 6,132 = 3.8, P = 0.01) reached signiÞcance. Neither the main e¤ect of lorazepam nor the interaction of lorazepam and time was signiÞcant. There were no signiÞcant baseline di¤erences between test days. Clinician-Administered Dissociative States Scale (CADSS) Figure 2 presents the total scores on the CADSS in healthy subjects (n = 23). Lorazepam did not signiÞ-cantly reduce the prominent perceptual e¤ects of ketamine. The RMANOVA performed on total CADSS scores revealed signiÞcant ketamine e¤ects (ketamine by time interaction : F 5,110 = 66.2, P = 0.0001) and a non-signiÞcant trend for lorazepam to reduce ketamine-induced perceptual alterations (ketamine by lorazepam by time interaction : F 5,110 = 2.6, P = 0.1).
Ketamine increased scores on the Þve CADSS subscales. The body perception subscale showed signiÞcant e¤ects of ketamine e¤ects (ketamine by time interaction : F 5,110 = 26.0, P = 0.0001). The most common reported experiences were alterations in the shape or position of limbs. Another common sensation was the feeling of ßoating or ßying, everything is going away and away and away ... it feels like Im ßying over the ocean really fast (ketamine day, subject no. 21).
Results from the environmental perception subscale of the CADSS are presented in Fig. 2 . The RMANOVA for the environmental perception subscale showed signiÞcant ketamine e¤ects (ketamine by time interaction : F 5,110 = 46.8, P = 0.0001). The ANOVA also revealed a trend for lorazepam to reduce ketamine e¤ects (ketamine by lorazepam by time : F 5,110 = 2.8, P = 0.08). Ketamine produced perceptual alterations within and across sensory domains. For example, one subject reported, I feel like Im on a roller coaster, everything is distorted ... the curtains look like they can reach out and touch me ... the wall seems to be doing a regeneration thing, like rabbits .. the creases in the sheets look like the face of a man ... when she says something, I can immediately see it in my brain (ketamine-lorazepam day, subject no. 16). Another subject noted, this machine takes on di¤erent shapes. The machine ßu¤ed up around me and then it got very ßat. You look like you are dancing under a strobe light ... you went through a few di¤erent body shapes, like cartoon Þgures (ketamine-lorazepam day, subject no. 9).
Feelings of unreality were also increased by ketamine. The RMANOVA performed on these data showed signiÞcant ketamine e¤ects (ketamine by time interaction: F 5,110 = 205.2, P = 0.0001). Feelings of unreality produced by ketamine included depersonalization, derealization, and identity-related alterations. Both ketamine and lorazepam worsened the sense of impaired memory and the combination of both drugs was worse than either drug alone. The ANOVA for memory impairment subscale indicated that ketamine e¤ects (ketamine by time interaction: F 5,110 = 32.2, P = 0.0001) were signiÞcant. There appeared to be a gender-related e¤ect of lorazepam on sense of impaired memory (lorazepam by gender: F 1,21 = 4.9, P = 0.04; lorazepam by time by gender: F 5,104 = 2.8, P = 0.07; ketamine by lorazepam by time by gender: F 5,105 = 3.3, P = 0.04). The data suggested that females (lorazepam by time: F 5,35 = 5.7, P = 0.004), but not males, found that lorazepam produced a subjective sense of impaired memory. Time perception was signiÞcantly slowed by ketamine (ketamine by time interaction e¤ects: F 5,110 = 26.5, P = 0.0001), although lorazepam did not alter this perceptual change.
Measures sensitive to impairments in frontal cortical function
Vigilance
Vigilance data are presented in Table 1 . RMANOVA revealed that the number of items correctly identiÞed on the continuous performance test of vigilance was reduced by lorazepam (F 1,21 = 16.4, P = 0.0006) and ketamine (F 1,21 = 6.7, P = 0.02) in healthy subjects (n = 22). However, the drug e¤ects were not interactive. As summarized in Table 1 , post-hoc within subjects contrasts revealed that the combination of ketamine and lorazepam reduced the number of correct responses relative to the placebo test day, but the combination did not di¤er signiÞcantly from either the ketamine or lorazepam test days. Similarly, RMANOVA revealed that both ketamine (F 1,21 = 6.7, P = 0.02) and lorazepam (F 1,21 = 16.4, P = 0.0006) increased the number of errors of omission in a non-interactive fashion. Post-hoc within subjects contrasts found that lorazepam, but not ketamine, increased omission errors relative to placebo. The combination of both medications increased omission errors relative to both placebo and ketamine. The RMANOVAs performed on both commission errors and response latency data were not signiÞcant.
Distractibility
As described in Table 1 , drug e¤ects on distractibility were in a similar direction, but more pronounced, than drug e¤ects on vigilance. RMANOVA revealed that ketamine (F 1,19 = 14.7, P = 0.001) and lorazepam (F 1,19 = 48.6, P = 0.0001) reduced the number of correct responses in healthy subjects (n = 20) on the distractibility task. RMANOVA also revealed a nonsigniÞcant trend for an interaction of ketamine and lorazepam e¤ects (F 1,19 = 2.1, P = 0.1). As described in Table 1 , post-hoc within-subjects contrasts revealed that lorazepam and the ketamine-lorazepam combination reduced the number of correct responses relative to placebo. The ketamine-lorazepam combination also reduced the number of correct responses relative to both ketamine and lorazepam test days. Similarly, both ketamine (F 1,19 = 14.7, P = 0.001) and lorazepam (F 1,19 = 48.6, P = 0.0001) increased omission errors. Post-hoc within subjects contrasts reported in Table 1 , found that ketamine, lorazepam, and the ketamine-lorazepam combination increased omission errors relative to placebo. The ketamine-lorazepam combination also increased omission errors relative to the ketamine and lorazepam test days. RMANOVA revealed that ketamine (F 1,19 = 4.6, P = 0.04) signiÞcantly increased errors of commission, while lorazepam e¤ects were not signiÞcant. Post-hoc within-subjects contrasts found that ketamine and the ketamine-lorazepam combination increased commission errors relative to placebo. The ketamine-lorazepam combination also increased commission errors relative to the lorazepam test day. No main e¤ects in the RMANOVA performed upon response latency data reached signiÞcance. Post-hoc within subjects contrasts found increased response latency on the ketamine-lorazepam test day relative to the placebo and ketamine test days.
Verbal ßuency
Ketamine produced dose-dependent decreases in verbal ßuency (F 1,22 = 24.5, P = 0.0001). Post-hoc within subjects contrasts (Table 1) revealed that ketamine and the ketamine-lorazepam combination reduced the rate of word generation relative to placebo. The ketamine-220 Based on healthy subjects completing the verbal ßuency task on all 4 test days (n = 23) e Based on healthy subjects completing the proverb interpretation task on all 4 test days (n = 23) f Based on healthy subjects receiving placebo ketamine / placebo lorazepam (n = 11), ketamine / placebo lorazepam (n =8), ketamine / lorazepam (n = 6), and placebo ketamine / lorazepam (n = 5) on their Þrst test day For comparisons to placebo / placebo by post-hoc within subjects contrasts. *P < 0.1; **P < 0.05; ***P < 0.01 For comparisons to active lorazepam / active ketamine by post-hoc within subjects contrasts. ¶ P < 0.1; ¶ ¶ P < 0.05; ¶ ¶ ¶ P < 0.05 For comparisons to placebo / placebo by post-hoc Fishers Protected LSD tests : $ P < 0.1; $$ P < 0.05; $$$ P < 0.01 For comparisons to active lorazepam / active ketamine by post-hoc Fishers protected LSD tests : § P < 0.1; § § P < 0.05; § § § P < 0.01 lorazepam combination also reduced the rate of word generation relative to the lorazepam test day.
Proverb interpretation
Three aspects of proverb interpretation were evaluated : concreteness, bizarreness, and failure to respond (Table 1) . RMANOVA performed on concreteness data revealed that both ketamine (F 1,22 = 27.3, P = 0.0001) and lorazepam (F 1,22 = 21.0, P = 0.0001), but not the interactive e¤ects of these drugs were associated with signiÞcant e¤ects. Post-hoc within subjects contrasts revealed that both ketamine and lorazepam increased the concreteness of proverb interpretations and that the combined medication e¤ects were signiÞcantly greater than either drug given individually. For example, in response to the proverb let sleeping dogs lie, one subject commented dont touch Suzy (his dog), shes not bothering anybody! (ketamine day, subject no. 1), while another subject said dont wake him up, hell start barking (ketamine-lorazepam day, subject no. 13).
A RMANOVA performed on bizarreness data indicated that ketamine (F 1,22 = 6.0, P = 0.02), but not lorazepam or the ketamine by lorazepam interaction had signiÞcant e¤ects. Post-hoc within-subjects contrasts performed on these data ( Table 1 ), revealed that the ketamine-lorazepam test day was associated with a signiÞcant increase in the bizarreness of proverb interpretations relative to both the placebo and lorazepam test days. There was also a trend for interpretations on the ketamine-lorazepam test day to be more bizarre than the ketamine test day. Bizarre proverb interpretations on ketamine often reßected thought disorder. For example, in response to one can ride a free horse to death, a subject responded, all I can associate with that is what I heard in church once when the priest said going to hell on roller skates in a basket (ketamine day, subject no. 1). Also, some interpretations were illogical, as illustrated by this interpretation of the proverb a stream cannot rise higher than its source: if you beget something, youre never going to grow up to be bigger than you are (ketamine-lorazepam day, subject no. 9). A RMANOVA performed on data assessing the failure to respond to a proverb with an interpretation of any kind revealed that ketamine (F 1,22 = 10.5, P = 0.004), but not lorazepam, signiÞcantly increased the failure to respond.
Wisconsin Card Sorting Test (WCST)
Ketamine, but not lorazepam, increased perseverative errors on the WCST. The ANOVA performed on perseverative errors data from the Þrst test day of each subject revealed signiÞcant drug e¤ects (F 3,26 = 3.6, P = 0.03). Post-hoc Fishers PLSD tests, presented in Table 1 , revealed that both ketamine and the ketaminelorazepam combination increased perseverative errors relative to placebo and lorazepam (ketamine versus lorazepam : P = 0.02). The ANOVA performed on percent perseverative error data was not signiÞcant. However, post-hoc Fishers PLSD tests indicated that both the ketamine (P < 0.05) and ketamine-lorazepam (P = 0.06) test days were associated with a greater percentage of perseverative errors than the lorazepam test day. The ANOVA performed upon non-perseverative errors was not signiÞcant.
Ketamine, but not lorazepam, reduced the number of categories successfully completed on the WCST. The ANOVA performed on this data revealed a signiÞcant drug e¤ect (F 3,26 = 7.6, P = 0.0009). Posthoc Fishers PLSD tests, reported in Table 1 , found that both ketamine and the ketamine-lorazepam test days signiÞcantly decreased the number of categories completed relative to placebo and lorazepam (ketamine versus lorazepam : P = 0.02). ANOVA performed on the number of trials to completion of the Þrst category data indicated a drug e¤ect (F 3,26 = 4.1, P = 0.02). The post-hoc Fishers PLSD tests performed on these data found that ketamine-lorazepam increased the number of trials relative to the placebo and lorazepam test days. There were no signiÞcant drug e¤ects on loss of set.
Learning and memory
Ketamine and lorazepam produced delay-dependent and interactive recall impairments (Fig. 3) . In the overall RMANOVA, the main e¤ects of ketamine (F 1,22 = 32.1, P = 0.0001), lorazepam (F 1,22 = 43.3, P = 0.0001), and the duration of delay between stimulus presentation and testing (F 2,44 = 158.0, P = 0.0001) were highly signiÞcant. The interactive e¤ects of ketamine and delay (F 2,44 = 16.2, P = 0.0001) and lorazepam and delay (F 2,44 = 21.6, P = 0.0001) were highly signiÞcant. Also, the interactive e¤ects of ketamine, lorazepam, and delay showed a non-signiÞcant trend toward signiÞcance (F 2,44 = 3.0, P = 0.06). In order to examine this trend, the ketamine and ketamine-lorazepam test days were directly compared. This comparison suggested that lorazepam potentiated the amnestic e¤ects of ketamine (F 8,176 = 2.8, P = 0.02). Post-hoc RMANOVAs were employed to evaluate the interactive e¤ects of ketamine and lorazepam at each level of delay. Neither ketamine nor lorazepam had signiÞcant e¤ects on immediate recall and their interactive e¤ects were not signiÞcant. Following a distraction, both ketamine (F 1,22 = 38.6, P = 0.0001) and lorazepam (F 1,22 = 28.0, P = 0.0001) e¤ects were highly signiÞcant, although their interactive e¤ects were not signiÞcant. Following a 10-min delay, ketamine e¤ects (F 1,22 = 14.1, P = 0.001), lorazepam e¤ects (F 1,22 = 50.3, P = 0.0001), and the interaction of ketamine and lorazepam e¤ects (F 1,22 = 5.7, P = 0.03) were signiÞcant.
Visual analog scales of mood states
Data from the visual analog scales are presented in Fig. 4 . Neither ketamine nor lorazepam signiÞcantly e¤ected visual analogue scales assessing irritability and sadness.
Anxiety
Ketamine increased self-rated anxiety and lorazepam did not signiÞcantly block this e¤ect. The RMANOVA performed on anxiety data found a signiÞcant ketamine by time interaction (F 6,126 = 8.2, P = 0.0001).
Drowsiness
Lorazepam increased self-reported drowsiness to a greater extent than ketamine and the combination of these medications potentiated the e¤ects of either drug administered individually. In the RMANOVA, lorazepam (lorazepam by time interaction : F 6,126 = 6.2, P = 0.0001), ketamine (ketamine by time interaction : F 6,126 = 2.5, P = 0.04), and the interactive e¤ects of ketamine, lorazepam, and time (F 6,126 = 2.4, P = 0.05) were signiÞcant.
High
Ketamine (ketamine by time interaction : F 6,126 = 29.2, P = 0.0001), but not lorazepam, produced a subjective sense of being high. One subject described the high as ethanol-like like when Im drinking, but Im hazier than when Im drinking (subject no. 6).
Neuroendocrine measures
Cortisol
Ketamine (ketamine by time interaction : F 3,66 = 55.4, P = 0.0001) increased cortisol levels and there was a trend for lorazepam (lorazepam by time interaction : F 3,66 = 3.4, P = 0.06) to have a similar e¤ect (Fig. 5) . In order to evaluate the possibility that stress related to emesis increased cortisol levels, the RMANOVA was 222 Fig. 4 Ketamine and lorazepam on visual analog scales of mood states in healthy subjects (n = 23), from top to bottom, anxiety, drowsiness, and high. Data are presented as mean values ± SEM. SigniÞcant increases from baseline by Dunnetts multiple t-tests are indicated : *P < 0.05; **P < 0.01. All other statistics are presented in the text. Test days are depicted as follows : (¡) placebo, (n) ketamine, (v) ketamine-lorazepam, and (q) lorazepam Fig. 3 Ketamine and lorazepam e¤ects on learning and memory as assessed by the recall item of the mini-mental state examination in healthy subjects (n = 23). Data are presented as mean values ± SEM for the peak decline in recall score from the pre-drug baseline for each test day. SigniÞcant decreases from baseline by Dunnetts multiple t-tests are indicated : *P < 0.01. All other statistics are presented in the text. Test days are depicted as follows : (¡) placebo, (n) ketamine, (v) ketamine-lorazepam, and (q) lorazepam repeated adding emesis as a between-subjects factor. This analysis revealed that emesis was associated with greater cortisol increases (emesis : F 1,22 = 9.4, P = 0.006; ketamine by time by emesis : F 3,63 = 13.1, P = 0.0002).
Prolactin
Ketamine (ketamine by time interaction : F 4,80 = 9.3, P = 0.004), and to a lesser extent lorazepam (lorazepam by time interaction : F 4,80 = 3.6, P = 0.03), increased prolactin levels (Fig. 5) . There also was a gender e¤ect related to lorazepam (lorazepam by time by gender : F 4,76 = 4.0, P = 0.03; ketamine by lorazepam by time by gender : F 4,76 = 2.5, P = 0.09). A post-hoc RMANOVA also indicated that the prolactin response was greater on the ketaminelorazepam test day than on the ketamine test day and that peak prolactin levels were higher in females than males (ketamine, lorazepam, time, and gender e¤ects : F 4,80 = 3.3, P = 0.04). When data from all test days were analyzed separately by gender, ketamine and lorazepam e¤ects remained signiÞcant for males (n = 15, ketamine by time : F 4,52 = 9.4, P = 0.0003; lorazepam by time : F 4,52 = 6.7, P = 0.002), but not females (n = 8, ketamine by time : F 4,24 = 4.2, P = 0.07; lorazepam by time : F 4,24 = 2.3, P = 0.1). The presence or absence of emesis also was added as a between-subjects factor in the analysis. Emesis was associated with increased prolactin responses to ketamine and there was a similar trend for lorazepam (ketamine by time by emesis : F 4,76 = 4.7, P = 0.03; lorazepam by time by emesis : F 4,76 = 2.7, P = 0.07; ketamine by lorazepam by time by emesis : F 4,76 = 2.3, P = 0.1).
HVA
As presented in Fig. 5 , ketamine and lorazepam blunted a test day decline in plasma HVA in healthy subjects (n = 23). The RMANOVA performed on HVA data revealed signiÞcant e¤ects of time (F 4,88 = 13.7, P = 0.0003), the ketamine by time interaction (F 4,88 = 3.9, P = 0.02) and the lorazepam by time interaction (F 4,88 = 2.8, P = 0.05). No other e¤ects were signiÞcant in the ANOVA. The addition of emesis and gender to the analysis did not e¤ect results. A post-hoc RMANOVA comparing the ketamine and ketaminelorazepam test days suggested that lorazepam blocked a ketamine-induced increase in HVA levels (F 4,88 = 3.3, P = 0.02).
Plasma lorazepam and ketamine levels
Ketamine and lorazepam did not show evidence of a pharmacokinetic interaction in this study and there were no signiÞcant changes detected in blood levels of either drug during the assessment period (Fig. 6) . The RMANOVA performed on lorazepam levels comparing the lorazepam and ketamine-lorazepam test days found a signiÞcant time e¤ect (F 1,20 = 17.1, P = 0.0001). No other main e¤ect or interaction was signiÞcant in this analysis. Also, there were no signiÞcant gender-related di¤erences in lorazepam blood levels and lorazepam did not signiÞcantly modulate ketamine levels. Similarly, the RMANOVA comparing the ketamine and the ketamine-lorazepam test days indicated a signiÞcant time e¤ect (F 2,12 = 16.7, P = 0.0003), but no other signiÞcant main e¤ects or interactions. 
Vital signs
Blood pressure
Ketamine increased systolic blood pressure in healthy subjects (n = 20; Fig. 7 ). The RMANOVA revealed signiÞcant e¤ects of ketamine (ketamine by time interaction : F 6,114 = 10.4, P = 0.0001) and the ketamine by lorazepam interaction (F 1,19 = 14.5, P = 0.001). Posthoc within subjects Dunnetts t-tests revealed signiÞcant increases from baseline (P < 0.01) on both the ketamine and ketamine-lorazepam test days. Ketamine increased diastolic blood pressure in healthy subjects (n = 21; Fig. 7 ). The RMANOVA revealed signiÞcant ketamine e¤ects (ketamine by time interaction : F 6,120 = 9.9, P = 0.0001).
Pulse
Ketamine also increased pulse rate in healthy subjects (n = 22; Fig. 7 ). The RMANOVA revealed signiÞcant ketamine (ketamine by time interaction (F 6,126 = 7.8, P = 0.0001) and lorazepam (lorazepam by time interaction : F 6,126 = 3.1, P = 0.007) e¤ects.
Respiratory rate
Neither ketamine nor lorazepam had signiÞcant e¤ects on respiratory rate. Baseline and peak increases in respiratory rate (respirations / min) for each test day were as follows : placebo : 18.6 ± 0.4 baseline, 1.4 ± 0.5 peak increase; ketamine : 18.9 ± 0.4 baseline, 1.3 ± 0.5 peak increase; ketamine-lorazepam : 18.7 ± 0.5 baseline, 1.2 ± 0.6 peak increase; lorazepam : 18.2 ± 0.5 baseline, 2.7 ± 0.6 peak increase.
Other responses
Motor function
Neither ketamine nor lorazepam a¤ected the rate of Þnger-tapping with the dominant hand (n = 17; placebo : 53.7 ± 1.4 taps; ketamine : 51.7 ± 2.1 taps; ketamine-lorazepam : 52.6 ± 1.4 taps; lorazepam : 54.3 ± 1.0 taps; ANOVA, ketamine : F 1,16 = 2.2, P = 0.2; lorazepam : F 1,16 = 0.6, P = 0.4). Lorazepam increased the rate of Þnger-tapping using the non-dominant hand, while ketamine e¤ects showed a trend in the opposite direction, although their e¤ects were not interactive (n = 14; placebo : 49.7 ± 1.5 taps; ketamine : 47.2 ± 1.7 taps; ketamine-lorazepam : 50.2 ± 1.4 taps; lorazepam : 51.4 ± 1.3 taps; ANOVA, ketamine : F 1,13 = 4.1, P = 0.07; lorazepam: F 1,13 = 5.5, P = 0.04).
Nystagmus
Fifteen subjects had nystagmus after receiving ketamine and the combination of ketamine and lorazepam; two subjects had nystagmus on ketamine, but not on ketamine-lorazepam; three subjects had nystagmus on ketamine-lorazepam, but not ketamine; and ten subjects did not have nystagmus during testing.
Emesis
Four subjects vomited after receiving ketamine and the combination of ketamine and lorazepam; six subjects vomited after receiving ketamine, but not on ketaminelorazepam; one subject vomited following administration of ketamine and lorazepam, but not ketamine alone; and 19 subjects did not su¤er incidents of emesis during testing.
Safety issues
On follow-up interview, no subject had lingering or recurrent physiological or psychological e¤ects such as nightmares or ßashbacks. A few subjects noted reduced sleep quality on the evenings of ketamine test days and reduced energy or concentration on the following day. 
Discussion
This study extended previous research in healthy humans indicating that ketamine e¤ects are not isomorphic to any known psychiatric illness. However, the data continue to suggest similarity of many ketamine e¤ects to symptoms and cognitive deÞcits associated with schizophrenia and dissociative states (Domino et al. 1965; Ghoneim et al. 1985; Øye et al. 1992; Krystal et al. 1994; Malhotra et al. 1996) . Ketamine produced positive symptoms associated with schizophrenia including paranoid and grandiose delusions, thought disorder, and illusions. Hallucinations, strictly deÞned as internally generated sensory experiences devoid of a sensory referent, were not produced by ketamine in this study. Ketamine produced negative symptoms, including blunted emotional responsivity, psychomotor retardation, and emotional withdrawal. It also produced perceptual alterations associated with dissociative states, including distorted sensory perceptions, altered body perception, feelings of unreality, slowing of time, and a sense of impaired memory. Ketamine impaired cognitive functions including delayed recall and performance on tests sensitive to frontal cortical impairment, without slowing Þnger-tapping. Mood e¤ects of ketamine included activation, anxiety, and high. Ketamine also increased plasma cortisol and prolactin levels and blunted a test day decline in plasma HVA.
Consistent with previous reports (File et al. 1982; Roache and Gri¦ths 1987; File 1992; Rush et al. 1993) , lorazepam reduced vigilance and increased distractibility, increasing omission rather than commission errors. It also reduced the capacity to interpret proverbs abstractly, without increasing the tendency to give bizarre responses. Lorazepam did not signiÞcantly reduce verbal ßuency or impair performance on the WCST. However, it produced a delay-dependent recall impairment in all subjects and a sense of impaired memory in females. Lorazepam had modest stimulatory e¤ects on plasma HVA, prolactin, and cortisol levels, contrasting with previous reports of inhibitory benzodiazepine e¤ects (Grandison 1983; Tuomisto and Mannisto 1985; Charney et al. 1986; Nutt and Cowen 1987) . The cause of the discrepancy between the earlier reports and the current study is not clear.
At the dose studied, lorazepam failed to block many undesirable ketamine e¤ects. Further, these drugs showed a range of interactions from antagonism to potentiation. Subhypnotic lorazepam reduced emotional distress and it tended to reduce distorted sensory perceptions associated with ketamine infusion. It also reduced the inability to produce a proverb interpretation, perhaps an indication of reduced thought blocking. However, it failed signiÞcantly to block psychotogenic, perceptual, cognitive, neuroendocrine and physiologic ketamine responses. Ketamine sedative e¤ects were intensiÞed by lorazepam. Lorazepam also potentiated ketamine amnestic actions, consistent with previous reports (Freuchen et al. 1976; Tobin 1982) . The current data suggested that the capacity of lorazepam to reduce emotional distress and to impair recall of disturbing ketamine e¤ects contributes to its established ability to improve ketamine anesthesia tolerability (Coppel et al. 1973; Fragen and Caldwell 1976; Kothary and Zsigmond 1977; Lilburn et al. 1978; Tucker et al. 1984) .
The absence of pharmacokinetic interactions is a strength of the ketamine-lorazepam combination. By potentiating sedative e¤ects, lorazepam permits the use of lower ketamine doses for anesthesia (Freuchen et al. 1976; Idvall et al. 1983 ). The apparent absence of pharmacokinetic interactions between ketamine and 225 Fig. 7 Ketamine and lorazepam e¤ects on systolic blood pressure (n = 23), diastolic blood pressure (n = 22), and pulse (n = 23) in healthy subjects (presented respectively, top to bottom). Data are presented as mean values ± SEM. SigniÞcant increases from baseline by Dunnetts multiple t-tests are indicated : *P < 0.05; **P < 0.01. All other statistics are presented in the text. Test days are depicted as follows : (¡) placebo, (n) ketamine, (v) ketaminelorazepam, and (q) lorazepam lorazepam suggests that the potentiation of ketamine sedation is mediated pharmacologically. In contrast, diazepam increases ketamine blood levels due to overlapping involvement of hepatic enzymes (Idvall et al. 1983) .
Previous human studies of NMDA antagonists provided evidence of ethanol-like e¤ects (Luby et al. 1959; Krystal et al., in press) . Similarly, the current study reported that ketamine produced a drug high. This euphoria was not produced by lorazepam nor did lorazepam signiÞcantly modulate the ketamine high. Unfortunately, this study did not assess whether lorazepam altered the discriminative properties of the ketamine high. This information would have been interesting in light of evidence that ethanol possesses both NMDA antagonist and GABA A facilitating e¤ects (Suzdak et al. 1986; Lovinger et al. 1989 ).
Lorazepam and ketamine-induced psychosis
The current data highlight challenges in studying contributions of reduced GABA A receptor function to the ketamine psychosis (Olney and Farber 1995) . GABAergic and glutamatergic systems are integral to cortico-striato-thalamic circuitry implicated in psychosis (Carlsson and Carlsson 1990; Grace 1991) . A growing body of research suggests that NMDA receptor stimulation activates GABAergic neurons (White 1989; Agmon and ODowd 1992) . NMDA antagonists reduce GABAergic inhibition in the cortex (Dingledine et al. 1986 ) and the septum (Giovanni et al. 1994 ). In addition, benzodiazepine pretreatment reduces NMDA antagonist stimulation of frontal cortical dopamine turnover (Bowers and Ho¤man 1989; Bowers and Morton 1992) and cortical metabolism (Oguchi et al. 1982; Åkeson et al. 1993) . They also weakly inhibit NMDA antagonist neurotoxicity (Olney et al. 1991; Olney and Farber 1995) . However, other data question the signiÞcance of subanesthetic ketamine e¤ects on GABA function. For example, subanesthetic doses of NMDA antagonists have modest e¤ects on GABA synthesis and metabolism (Leonard and Tonge 1970; Manor et al. 1995) , may reduce GABA reuptake (Wood and Hertz 1980) , and they maintain extracellular GABA levels in the frontal cortex (Moghaddam, personal communication) .
The current study is limited in its capacity to evaluate GABAergic modulation of ketamine psychosis. Lorazepam doses that produce anxiolysis, amnesis, and sedation were not e¤ective in preventing ketamine psychosis. However, the anesthesia literature suggests that the IV administration of lorazepam at a higher dose than employed in the current study, 4 mg, reduces ketamine psychosis (Dundee et al. 1977) . At this lorazepam dose, sedative e¤ects interfere with prospective behavioral assessments and amnestic e¤ects could interfere with retrospective self-reports. Future studies should examine multiple lorazepam doses, perhaps with IV infusion, as well as multiple ketamine doses to examine further lorazepam-ketamine interactions.
Ketamine, lorazepam, and dissociative states
The capacity of ketamine to elicit sensory and identity-related perceptual distortions in healthy individuals provided further evidence that deÞcits in NMDA receptor function might contribute to the genesis of dissociative states (Krystal et al. 1994) . Ketamine actions in networks modulating sensory association cortex (Corrsen and Domino 1966) and sensory Þltering functions of the thalamus have been implicated in ketamine-induced perceptual alterations . There was a trend for lorazepam to reduce alterations in sensory perception. However, other dissociative symptoms were not reduced by lorazepam. The limited e¦cacy of subhypnotic lorazepam to prevent perceptual alterations in the current study may be consistent with the important, but limited, e¦cacy of benzodiazepines in the treatment of dissociative states (Kluft 1987) . Dissociative disorders produce signiÞcant su¤ering and disability, but are without established e¦cacious pharmacotherapies (Kluft 1987) . The current Þndings support further investigation of glutamatergic models in developing novel pharmacotherapies for dissociative disorders.
Ketamine, lorazepam, and frontal cortical functions
This study replicated and extended earlier Þndings (Krystal et al. 1994) suggesting that ketamine impairs functions associated with the frontal cortex. This study and others (Krystal et al. 1994) suggest that performance on the Mini-Mental State Examination, Þnger-tapping, and aspects of attention are preserved during subanesthetic ketamine administration. However, ketamine e¤ects cannot be said to be selective for functions associated with the frontal cortex. As NMDA receptors are widely distributed in the brain (Kornhuber et al. 1989) , ketamine e¤ects on tests sensitive to frontal cortical impairment could arise from ketamine actions within the frontal cortex or at extrinsic modulatory sites. Further, ketamine appears to modulate a broad spectrum of cognitive functions.
Comparisons of ketamine and lorazepam e¤ects highlighted the prominence of ketamine e¤ects of tasks associated with the frontal cortex. Both ketamine and lorazepam increased omission errors on the vigilance and distractibility tasks without increasing response latency. They also produced comparable levels of concreteness during proverb interpretation. However, ketamine, but not lorazepam, increased commission errors on the continuous performance tasks, reduced verbal ßuency, produced bizarre proverb interpretations, and impaired WCST performance. While these ketamine e¤ects could be ascribed to the frontal cortex, they may also reßect dysfunction in temporoparietal regions involved in interpretive functions (Wise, et al. 1991) or dysregulation of anterior cingulate gyrus activity implicated in the allocation of attention (Pardo et al. 1990; Lahti et al. 1995; McCarthy et al. 1996) .
The current data also highlight the complexity of the WCST as a measure of executive functions. Lorazepam-induced attention impairments and concreteness in proverb interpretation were not associated with increased perseverative errors or reduced categories completed on the WCST. Thus, the WCST may be completed using strategies that do not require a high degree of abstract reasoning as long as other cortical functions remain intact. In contrast, the associative aspects of abstract cognition impaired by ketamine appear to be more directly related to the planning, problem-solving, mental set-shifting, and feedbackintegrating functions evaluated by the WCST.
Ketamine-induced impairments in frontal cortical function were previously linked to BPRS negative symptoms in healthy subjects (Krystal et al. 1994 ). Negative symptoms have been previously described in patients with frontal cortical injury (Stuss and Benson, 1986) or schizophrenia (Wolkin et al. 1992 ). Benzodiazepines may be helpful as an adjunctive pharmacotherapy in the treatment of negative symptoms in schizophrenics (cf. Wolkowitz and Pickar 1991) . However, lorazepam increased ketamine-induced negative symptoms and did not improve performance on frontal cortical tasks. In the current study, interactive drug sedative e¤ects were evident on the attention tasks. These sedative e¤ects confound the interpretation of the negative symptom data.
NMDA antagonist e¤ects in humans are of signiÞcant interest because of their potential relevance to psychosis, dissociation, substance abuse, and cognitive function. In the current study, lorazepam modulated many ketamine e¤ects, emphasizing the importance of GABA-glutamate interactions in the brain. Further, the current study does not rule out the possibility that higher lorazepam doses might reduce ketamine-induced psychosis. However, the failure of lorazepam to block the ketamine psychosis in the current study highlights limitations of the current knowledge base. Novel pharmacologic approaches should be similarly explored to determine whether they provide a more e¤ective antagonism of ketamine-induced psychosis and thought disorder.
